ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BEAM vs UNH // EV/EBITDA & P/E VALUATION

Beam Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BEAM 2 — UNH 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BEAM VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BEAM UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 88.57% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.10% 11.47% -43.57 UNH /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 16.4x — TIE /valuation <GO>
Free Cash Flow Yield -12.09% 6.48% -18.57 UNH /fcf-yield <GO>
Operating Margin -60.00% 4.82% -64.82 UNH /operating-margins <GO>
Net Profit Margin -57.20% 3.14% -60.34 UNH /net-margins <GO>
Revenue Growth (YoY) 120.00% 6.46% +113.54 BEAM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.28% -2.28 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.00 3.12 +2.88 BEAM /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 UNH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — 6.74% — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 57.7 59.2 -1.51 UNH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.33 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 17.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.98B $368.83B -$365.85B UNH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BEAM REV UNH REV BEAM GROSS % UNH GROSS % BEAM FCF UNH FCF
FY 2025 $139.7M $447.57B — 88.7% -$360.0M $16.07B
FY 2024 $63.5M $400.28B — 88.3% -$356.2M $20.70B
FY 2023 $377.7M $371.62B — 89.6% -$149.2M $25.68B
FY 2022 — $324.16B — 89.6% — $23.40B
FY 2021 — $287.60B — 89.2% — $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BEAM // BETA —
UNH // BETA 0.33